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Summary
Cell cycle regulators such as E2F1 and retinoblastoma (RB) play crucial roles in the control of adipogenesis, mostly by
controlling the transition between preadipocyte proliferation and adipocyte differentiation. The serine-threonine kinase
cyclin-dependent kinase 4 (cdk4) works in a complex with D-type cyclins to phosphorylate RB, mediating the entry of
cells into the cell cycle in response to external stimuli. Because cdk4 is an upstream regulator of the E2F-RB pathway,
we tested whether cdk4 was a target for new factors that regulate adipogenesis. Here we find that cdk4 inhibition impairs
adipocyte differentiation and function. Disruption of cdk4 or activating mutations in cdk4 in primary mouse embryonic
fibroblasts results in reduced and increased adipogenic potential, respectively, of these cells. We show that the effects
of cdk4 are not limited to the control of differentiation; cdk4 also participates in adipocyte function through activation
of PPARγ.Introduction
Cell proliferation and differentiation have been considered to
be mutually exclusive events; however, a close relationship has
been established between both cell processes during the adi-
pocyte differentiation program (reviewed in Fajas [2003]). Reen-
try into the cell cycle is one of the key events taking place in
early adipogenesis, since inhibition of DNA synthesis at this
stage blocks differentiation (Patel and Lane, 2000; Reichert
and Eick, 1999). Like in most cells, the transition from growth
arrested preadipocytes into S phase likely depends on the re-
activation of the G1 cyclins/cdks and the retinoblastoma pro-
tein RB-E2F pathway that controls the G1/S transition of the
cell cycle. Association of E2Fs with proteins of the RB family
facilitates active repression through recruitment of histone de-
acetylases (Brehm et al., 1998; Magnaghi-Jaulin et al., 1998).
Upon reentry into cell cycle of these growth-arrested preadipo-
cytes, the members of the retinoblastoma family are phosphor-
ylated by the cyclin/cdk holoenzymes, releasing the E2F com-
plex, resulting in the activation of the E2F target genes (Richon
et al., 1997). We have previously shown that cell cycle regula-
tors such as E2F1 and RB play crucial roles in the control of
adipogenesis, mostly through the control of the transition be-
tween preadipocyte proliferation and adipocyte differentiation.
E2F1 positively regulates the expression of peroxisome prolif-
erator-activated receptor γ (PPARγ; Fajas et al., 2002b), which
is the master regulator of adipocyte differentiation, whereas RB
inhibits PPARγ activity through direct protein-protein interaction
(Fajas et al., 2002a). PPARγ is a ligand-activated transcription fac-
tor belonging to the nuclear receptor superfamily. PPARγ isCELL METABOLISM : OCTOBER 2005 · VOL. 2 · COPYRIGHT © 2005 ELpreferentially expressed in the adipose tissue, and upon activa-
tion by fatty acids derivatives or antidiabetic thiazolidinediones,
PPARγ drives the expression of several adipocyte-specific
genes, such as the fatty acid binding protein (aP2; for review
see Debril et al. [2001]). Since cyclin-dependent kinase 4
(cdk4), which mediates the commitment of the cells to enter
the cell cycle in response to external stimuli (reviewed in Or-
tega et al. [2002]) is an upstream regulator of the E2F-RB path-
way, we hypothesized that cdk4 would be a good target in the
search for new factors that regulate adipogenesis. Cdk4−/−
mice develop insulin-deficient diabetes due to reduced β cell
pancreatic mass. These mice have reduced body weight and
are smaller (Rane et al., 1999; Tsutsui et al., 1999). Further-
more, mice expressing an activating mutation of cdk4 (R24C)
that cannot bind the cell cycle inhibitor P16INK4a show pan-
creatic hyperplasia and increased body weight.
We show in this study that cdk4 participates in adipose tis-
sue biology, not only through the control of the clonal expan-
sion phase of adipogenesis but also regulating PPARγ activity
and terminal differentiation and function of adipocytes.
Results
Cdk4 is expressed and active in nonproliferating
mature adipocytes
While evaluating the expression of cell cycle regulators impli-
cated in the transition between preadipocyte proliferation and
adipocyte differentiation, we found that cdk4 protein was ex-
pressed at similar levels at all stages of differentiation of 3T3-
L1 preadipocytes as measured by immunofluorescence assaysSEVIER INC. DOI 10.1016/j.cmet.2005.09.003 239
A R T I C L EFigure 1. Cdk4 is expressed during adipogenesis and in fully differentiated human and mouse adipocytes
A) Analysis of cdk4 and PPARγ coexpression by immunofluorescence in 3T3-L1 cells induced to differentiate. Days of differentiation indicate confluent (day 0), reentry
into cell cycle (day 1), and terminally differentiated (day 5) cells. PPARγ-expressing cells are labeled in green, whereas cdk4-expressing cells are in red. Nuclei were
visualized with Hoechst staining.
B) Detailed analysis by confocal microscopy of cdk4 (red) and PPARγ (green) expression in a representative single cell.
C) Quantification of the mRNA expression by real-time PCR of the adipogenic marker aP2 at the indicated times of differentiation. Results were normalized by the
expression of the β actin mRNA. Results are representative of two independent experiments in the subsequent panels.
D) Quantification of the expression of cdk4 and PPARg mRNA during differentiation of human primary preadipocytes at days 0 or at day 13 of differentiation.
E) Immunohistochemical analysis of cdk4 expression in histological sections of mouse adipose tissue. Red arrows indicate adipocytes expressing cdk4.
F) Cdk4 activity in adipocytes. SDS-PAGE autoradiography showing phosphorylated purified RB by immunoprecipitated cdk4 from confluent, nondifferentiated 3T3-
L1 preadipocytes (d0, lane 1), differentiated 3T3-L1 adipocytes (d7, lane 2), or from primary mouse adipocytes freshly prepared from white adipose tissue (WAT, lane
5). Immunoprecipitates with rabbit antiserum were used as negative control (mock, lanes 3, 4, and 6). Purified cdk6/cycD3 complex was used instead of the immuno-
precipitates as positive control (lane 7).
G) Quantification of cdk4 protein expression (right axis) and BrdU incorporation (left axis) by immunofluorescence in proliferating (day −1) or postconfluent 3T3-L1 cells
stimulated with differentiation medium for 7 days as described under Experimental Procedures. Percentage of cdk4-expressing 3T3-L1 cells, which are BrdU positive
at the indicated days of differentiation. Results are the mean of at least 500 cells in two independent experiments.(Figure 1A). Interestingly, we observed changes in the cellular
localization of cdk4 by confocal microscopy. At confluence
(day 0), cdk4 expression was mainly cytoplasmic, whereas dif-
ferentiated adipocytes (day 5) expressed mainly nuclear cdk4
(Figure 1A). Interestingly, nuclear colocalization of cdk4 and
PPARγ could be observed by confocal microscopy in differenti-
ated 3T3-L1 adipocytes (Figure 1B). Differentiation of the cells
was quantified by measuring the mRNA expression of the adi-
pogenic marker aP2 (Figure 1C). Similar to 3T3-L1 cells, no
significant changes in the expression of cdk4 mRNA were ob-
served during differentiation of primary human preadipocytes,240whereas PPARγ expression was increased (Figure 1D). Consis-
tent with these experiments we found that cdk4 was expressed
in mature adipocytes of mouse adipose tissue as assessed by
immunohistochemical analysis of mouse adipose tissue sec-
tions (Figure 1E). These results suggested a role of cdk4 in
adipose tissue biology and differentiation.
To further assess the participation of cdk4 in differentiated
adipocytes, kinase activity experiments were performed. Im-
munoprecipitated cdk4 from either differentiated 3T3-L1 adipo-
cytes (Figure 1F, lane 2) or freshly prepared primary mice adi-
pocytes (Figure 1F, lane 5) was able to phosphorylate a purifiedCELL METABOLISM : OCTOBER 2005
Cdk4 and adipogenesisrecombinant retinoblastoma protein in vitro, indicating that
cdk4 was indeed active in adipocytes (Figure 1F). No phos-
phorylation of RB was observed when rabbit antiserum was
used to immunoprecipitate the extracts (Figure 1F, lanes 3, 4,
and 6). Cdk4 was also inactive in quiescent, nondifferentiated
3T3-L1 preadipocytes (Figure 1F, lane 1). Since cdk4 activity is
related to the control of cell cycle, we next evaluated DNA syn-
thesis in 3T3-L1 adipocytes by BrdU incorporation assays. As
expected, most of cdk4-expressing 3T3-L1 preadipocytes in-
corporated BrdU, indicating that these cells were proliferating
(Figure 1G). In contrast, only a small proportion of cdk4-
expressing 3T3-L1 adipocytes were positive for BrdU incorpo-
ration (Figure 1G), demonstrating that cdk4 was expressed in
nonproliferating cells and suggesting that the detected cdk4
activity in differentiated cells could be independent of the con-
trol of cell cycle (Figures 1F and 1G).
Inhibition of cdk4 activity impairs adipogenesis
Participation of cdk4 in adipogenesis was further studied. Dif-
ferentiation of 3T3-L1 cells was induced with a typical hor-
monal mix either in the absence or in the presence of the
specific cdk4 inhibitor 2-Bromo-12,13-dihydro-5H-indolo(2,3-
a)pyrrolo (3,4)carbazole (IDCX) (Zhu et al., 2003). Oil Red O
staining indicated that IDCX was a potent inhibitor of 3T3-L1
adipocyte differentiation (Figure 2A). This was consistent with
a decrease in the expression of the adipogenic markers PPARγ
and aP2 in the presence of the inhibitor (Figure 2B). Similar
results were observed when the cdk4 inhibitor I3M was used
(data not shown). The inhibition of cdk4 kinase activity in these
cells was demonstrated by in vitro kinase assays (data not
shown).
After hormonal induction, 3T3-L1 preadipocytes reenter the
cell cycle before terminally differentiating into adipocytes. This
clonal expansion phase (days 1 and 2) is required for the differ-
entiation process of the 3T3-L1 cells. It would be therefore
plausible that cdk4 participates in adipogenesis by inducing
the proliferative clonal expansion phase. This was consistent
with the observation that cdk4 inhibition with IDCX abrogated
the clonal expansion of hormonally induced 3T3-L1 cells as
analyzed by BrdU incorporation experiments (Figure 2C, day
1). Furthermore, the expression of the cell cycle markers cyclin
E and cyclin B was decreased in the presence of IDCX, consis-
tent with the BrdU incorporation experiments (Figure 2D). To
further elucidate whether participation of cdk4 was limited to
the control of the proliferative phase of the adipocyte differenti-
ation process, we inhibited cdk4 activity with IDCX after com-
pletion of clonal expansion at day 2. Interestingly, adipocyte
differentiation was also inhibited under these conditions as as-
sessed by Oil Red O staining (Figure 2E) and by the expression
of adipocyte marker genes (Figure 2F). BrdU incorporation
studies demonstrated that the cells were not proliferating at
the time of IDCX incubation (Figure 2G). These results sug-
gested that active cdk4, in addition to its role in the control of
the cell cycle during the clonal expansion phase, is also re-
quired during terminal differentiation in a cell cycle-indepen-
dent manner.
A second cellular model was next used to further demon-
strate the implication of cdk4 in adipocyte differentiation.
F442A cells were induced to differentiate into adipocytes in the
absence or in the presence of IDCX. Lipid incorporation (data
not shown), as well as the expression of adipocyte markers,CELL METABOLISM : OCTOBER 2005indicated that cdk4 inhibition resulted in decreased adipocyte
differentiation when compared with F442A differentiated in the
absence of IDCX (Figure 2H). As for 3T3-L1 cells, F442A pre-
adipocytes reentered the cell cycle after insulin induction of
differentiation. Surprisingly, IDCX did not prevent reentry into
the cell cycle of differentiating cells as measured by BrdU in-
corporation (Figure 2I) and expression of cyclin E and cyclin B
(Figure 2J). Yet, IDCX decreased differentiation to a similar level
to that observed in 3T3-L1 cells, suggesting that, in F442A
cells, cdk4 inhibition prevents adipogenesis independently of
the control of the cell cycle.
Cdk4 overexpression enhances adipogenesis
To test the hypothesis that cdk4 is a positive factor for adipo-
cyte differentiation, a 3T3-L1 stable cell line constitutively ex-
pressing cdk4 was generated by retroviral infection (pBabe-
cdk4). Oil Red O staining indicated an increased capacity to
differentiate into adipocytes of pBabe-cdk4 cells compared to
3T3-L1 cells infected with an empty retrovirus (pBabe) 4 days
after induction of adipogenesis (Figure 3A). Overexpression of
cdk4 could not bypass, however, the requirement of differentia-
tion medium in order to differentiate (data not shown). Interest-
ingly, 3T3-L1 cells infected with a retrovirus expressing a ki-
nase-dead cdk4 mutant (pBabe-K35M) lost their capacity to
differentiate (Figure 3A), suggesting that the positive effects on
adipogenesis are mediated by the kinase activity of cdk4. Cdk4
protein was highly expressed, as expected, in pBabe-cdk4 and
pBabe-K35M cells, compared to pBabe 3T3-L1 cells (Figure
3B). Consistent with the Oil Red O assays, real-time PCR
analyses showed increased levels of aP2 up to 2-fold in
pBabe-cdk4-3T3-L1 cells, whereas no such increase was ob-
served in cells infected with pBabe-K35M (Figure 3B).
Mice deficient for cdk4 have decreased body weight (Rane
et al., 1999; Tsutsui et al., 1999), decreased fat mass, and
smaller adipocytes (our unpublished data). In contrast, mice
expressing a hyperactive cdk4 mutant have increased weight
(Rane et al., 1999), increased fat mass, and bigger adipocytes
(our unpublished data). The phenotypes of cdk4−/− and
cdk4R24C mice suggest a defect in adipose tissue homeosta-
sis. However, cdk4−/− mice are hypoinsulinemic as a result of
diabetes, and cdk4R24C mice develop pancreatic islet β cell
hyperplasia with increased production of insulin. It could be
therefore possible that the effects on adipogenesis in these
mice are secondary to insulin signaling and not directly related
to adipose tissue development. To test this notion, we com-
pared the capacity of cdk4−/− or cdk4R24C primary isolated
MEFs to differentiate into adipocytes in vitro in response to
hormone stimulation. Adipocytes were scored using Oil Red
O staining to detect lipid droplets and mRNA expression of
adipogenic markers was quantified. Consistent with a direct
effect of cdk4 in adipogenesis, the capacity of cdk4−/− MEFs
to differentiate into adipocytes was totally inhibited (Figure 3C).
Conversely, hormonally stimulated cdk4R24C MEFs showed a
robust increase in their capacity to differentiate into adipocytes
in vitro when compared to wild-type MEFs (Figure 3C). Further-
more, when expression of cdk4 was rescued by retroviral infec-
tion, cdk4−/− MEFs could normally differentiate, demonstrating
that inhibition of differentiation in cdk4−/− MEFs was directly
the result of the lack of cdk4 (Figure 3C). Reexpression of cdk4
in cdk4−/− MEFs was verified by QPCR analysis (Figure 3D).
Gene expression analysis of the adipose tissue-specific gene241
A R T I C L EFigure 2. Cdk4 inhibitors impair adipogenesis
A–G) Representative micrographs of Oil Red O staining of 3T3-L1 cells differentiated in vitro for 7 days in the presence or absence of the indicated concentration of
the specific cdk4 inhibitor IDCX added either at the induction of differentiation (A) or two days after induction (E). mRNA of differentiated cells was analyzed for the
expression of the adipocyte markers aP2 and PPARg by quantitative PCR in response to IDCX added either before (B) or after (F) the clonal-expansion phase. Results
were normalized by the expression of the b actin RNA. Cell cycle status of the cells was analyzed by quantification of BrdU incorporation either in the absence or
presence of 0.5 M IDCX added before (C) or after (G) the clonal-expansion phase. mRNA expression of cyclin E and cyclin B was quantified at different times of
adipocyte differentiation (d0, d1, d2, d6) in the absence or in the presence of IDCX added before the clonal-expansion phase (D). Results are representative of two
independent experiments in the subsequent panels.
H–J) Analysis of the expression of adipocyte markers aP2 and PPARg 6 days after initiation of differentiation of F442A cells in the absence or presence of IDCX (H).
Cell cycle status of the cells was analyzed by quantification of BrdU incorporation either in the absence or presence of 0.5 M IDCX added at initiation of differentiation
(I). mRNA expression of cyclin E and cyclin B was also quantified at different times of F442A adipocyte differentiation (d0, d1, d2, d6) in the absence or in the presence
of IDCX added before the clonal expansion phase (J).aP2 further demonstrated the decreased and increased num-
ber of cdk4−/− and cdk4R24C MEF-derived adipocytes, re-
spectively, as well as the increased number of adipocytes in
rescued cdk4−/− MEFs (Figure 3E). Taken together, these data
suggest that cdk4 directly stimulates adipogenesis.
Cdk4 participates in adipocyte biology
In addition to its participation in adipocyte differentiation, we
next wanted to analyze whether cdk4 have a role in adipocyte
biology. First, we performed glucose uptake experiments in
fully differentiated 3T3-L1 adipocytes in response to cdk4 in-242hibitors. Twenty-four hour IDCX treatment inhibited in a dose-
dependent manner the incorporation of radioactive glucose
into adipocytes in response to insulin (Figure 4A). Interestingly,
basal glucose uptake was increased upon incubation of high
doses of IDCX when compared to cells treated with vehicle
only (Figure 4A). To exclude the possibility that the observed
differences in the response of the cells to insulin were the result
of a distinct stage of differentiation of the cells, the expression
of aP2 mRNA was measured, and no differences were found
(Figure 4B).
Consistent with decreased insulin sensitivity, the expressionCELL METABOLISM : OCTOBER 2005
Cdk4 and adipogenesisFigure 3. Cdk4 overexpression increases adipocyte differentiation
A) Micrographs of Oil Red O staining of 3T3-L1 adipocytes retrovirally infected with either an empty vector (pBabe), a retrovirus encoding for cdk4 (pBabe-cdk4), or a
retrovirus encoding for kinase-dead cdk4 mutant (pBabe-K35M) 4 days after induction of adipogenesis.
B) mRNA quantification by real-time PCR of the adipocyte marker aP2 and cdk4 mRNA. Results were normalized by the expression of the b actin RNA. Results are
representative of two independent experiments in the subsequent panels.
C) Oil Red O staining of MEFs from either wild-type (cdk4+/+), cdk4-deficient (cdk4−/−) or hyperactive cdk4R24C mutant mice induced to differentiate into adipocytes
for 7 days. Cells were infected with retrovirus expressing either an empty vector (pBabe) or retrovirus expressing cdk4 (pBabe-cdk4) as indicated.
D) Quantification of the mRNA expression by real-time PCR of cdk4 in cells used in (C). Results were normalized by the expression of the b actin RNA in all
subsequent experiments.
E) aP2 mRNA expression analyzed by real-time PCR in the same cells used in (C).of genes such as Glut-4, insulin receptor (IR), insulin receptor
substrate-1 (IRS1), IRS2, and PI3K, which are key proteins in
glucose transport and glucose homeostasis, was also de-
creased in the presence of IDCX (Figure 4C). Strikingly, Glut-1
mRNA expression was increased upon incubation with IDCX,
which was consistent with the increased basal glucose uptake
observed under these conditions.
Finally, the expression of genes implicated in lipogenesis
was analyzed. Fatty acid synthase (FAS) and phosphoenol py-
ruvate carboxy kinase (PEPCK) mRNA expression was de-
creased in IDCX-treated adipocytes (Figure 4D), which wasCELL METABOLISM : OCTOBER 2005consistent with decreased lipid load in these cells. No changes
in the expression of genes implicated in lipolysis was observed
in these cells (data not shown). These results suggested that
cdk4 inhibition impaired adipocyte function decreasing lipo-
genesis and glucose transport and metabolism in these cells.
Cdk4 activates PPARγ through direct interaction
PPARγ plays a crucial role in the adipocyte differentiation pro-
cess. Any factor modulating PPARγ activity has major effects
on adipogenesis. We therefore tested the ability of cdk4 to acti-
vate PPARγ in transient transfection experiments in COS cells,243
A R T I C L EFigure 4. Participation of cdk4 in adipocyte biology
A) Glucose uptake experiments in 3T3-L1 adipocytes treated with increasing dose of IDCX. The values represent the fold induction of radioactive glucose uptake by
insulin load of the cells relative to basal conditions of cells treated with vehicle. Values are the result of two independent experiments in the subsequent panels.
B) Quantification of aP2 mRNA expression of cells used in (A).
C) Quantification of mRNA expression in 3T3-L1 adipocytes of genes involved in glucose transport and metabolism in response to 1 M of IDCX.
D) Analysis by real-time PCR of the expression of genes implicated in lipogenesis in 3T3-L1 adipocytes treated with 1M IDCX.using a PPARγ-responsive luciferase reporter (PPRE-TK-Luc)
and PPARγ and cdk4 expression vectors. A 3-fold induction of
luciferase activity was observed upon transfection of limiting
concentrations of PPARγ in the presence of pioglitazone. This
induction was significantly increased up to 6-fold by cotrans-
fection of cdk4 (Figure 5A), suggesting that cdk4 activates
PPARγ. Interestingly, the cdk4-K35M kinase-dead mutant was
not able to increase PPARγ activity (Figure 5A), which was con-
sistent with the lack of effects of this mutant on adipogenesis
(Figure 3A). Furthermore, cdk4 inactivation by the specific cdk4
inhibitor IDCX resulted in the attenuation, in a dose-dependent
manner, of PPARγ activation by pioglitazone (from 3- to 1-fold;
Figure 5B). Consistent with these results, we found that either
pioglitazone or rosiglitazone treatment of cdk4−/− MEFs in
which cdk4 expression was rescued by retroviral infection re-
sulted in a 3-fold induction of the PPARγ target aP2 mRNA,
whereas only a 1.5-fold induction was observed when cdk4−/−
MEFs infected with empty retrovirus were treated (Figure 5C,
left panel). PPARγ was equally expressed in both cell lines (Fig-
ure 5C, right panel). Next, to test whether the increase in
PPARγ activity in the presence of cdk4 was the consequence
of an interaction with PPARγ, total cell extracts from PPARγ-
and cdk4-transfected COS cells were immunoprecipitated with
an anti-PPARγ antibody. A 33 kDa protein was recognized in
the immunoprecipitates by an anti-cdk4 antibody, indicating244that cdk4 interacted in vivo with PPARγ (Figure 5D). Further-
more, when extracts from cdk4-expressing differentiated 3T3-
L1 adipocytes were immunoprecipitated using an anti-PPARγ
antibody, endogenous cdk4 protein was associated to PPARγ
(Figure 5E). Deletion experiments in the cdk4 protein indicated
that the K35 amino acid in the ATP binding domain of cdk4
was not implicated in the PPARγ interaction. However, deletion
of aa 203–295 abolished binding to PPARγ (Figure 5F). Interest-
ingly, GST pull-down experiments indicated that cdk4 is able
to bind both, the AB domain of PPARγ and the DEF domain,
which contain the ligand-independent and the ligand-depen-
dent transactivation domains, respectively (Figure 5G).
Finally, to further prove that cdk4 is associated with PPARγ
and that it activates PPARγ-mediated transcription, chromatin
immunoprecipitation studies of the aP2 promoter were per-
formed in both nondifferentiated and differentiated 3T3-L1 adi-
pocytes. A 200 bp fragment of the mouse aP2 promoter con-
taining the binding site of PPARγ was amplified by PCR when
anti-cdk4, anti-PPARγ, or anti-acetylated histone H4 antibodies
were used to immunoprecipitate chromatin from differentiated
3T3-L1 cells (Figure 5H). No amplification product was ob-
served when immunoprecipitated chromatin from confluent,
nondifferentiated 3T3-L1 preadipocytes was used as template
(data not shown). The results of the ChIP assays demonstrate
that the complex cdk4-PPARγ is present in the promoter ofCELL METABOLISM : OCTOBER 2005
Cdk4 and adipogenesisFigure 5. Cdk4 interacts with PPARγ and activates PPARγ target genes
A) Relative luciferase activity as determined after transfection of COS cells with the PPARγ-responsive reporter construct J3-TK-Luc and treated with the PPARγ agonist
pioglitazone. Cells were transfected with an expression vector for PPARγ in the absence or presence of increasing concentrations of either a cdk4 expression vector
or a cdk4 mutant (K35M) vector. Results were normalized for the expression of a β-gal reporter. Values are the mean of three independent experiments. An asterisk
depicts statistically significant differences.
B) Same transfection as in (A) using J3-TK-Luc and PPARγ vectors. Cells were incubated with increasing concentrations of the specific cdk4 inhibitor IDCX (1–5 M).
Results were normalized for the expression of a β-gal reporter. Values are the mean of three independent experiments. An asterisk depicts statistically significant differ-
ences.
C) Quantitative real-time PCR showing mRNA expression levels of aP2 (left panel) in the absence or in the presence of 10−6 M pioglitazone or 10−6 M rosiglitazone.
Expression levels of PPARγ are shown in the right panel. Values are the mean of three independent experiments.
D) Coimmunoprecipitation of PPARγ and cdk4 from COS cells transfected (lanes 2, 4, and 6) or not (NT, lanes 1, 3, and 5) with PPARγ and cdk4 expression vectors.
Extracts are immunoprecipitated with either an anti-PPARγ antibody (PPARγ, lanes 5 and 6) or preimmune serum (Mock, lane 3 and 4) and revealed by an anti-cdk4
antibody. One-half of the input is shown as a control (lanes 1 and 2).
E) Coimmunoprecipitation of PPARγ and cdk4 from differentiated 3T3-L1 adipocytes expressing cdk4. Immunoprecipitation with anti PPARγ (lane 3) or IgGs (lane 2)
was followed by Western blot anti-cdk4. Input is indicated in lane 1.
F and G) GST pull-down assays showing details of the PPARγ-cdk4 interaction. In vitro translated 35S-radiolabled PPARγ (E) or cdk4 protein (F) were incubated
respectively with different deletion mutants of cdk4 (E) or PPARγ (F). Mutants are described under the Experimental Procedures section.
H) Chromatin immunoprecipitation (ChIP) assay demonstrating binding of cdk4 to the PPARγ binding site in the aP2 promoter. Crosslinked chromatin from 3T3-L1 cells
differentiated during 7 days was incubated with antibodies against acetylated histone H4 (lane 3), actin (lanes 4), PPARγ (lane 5), cdk4 (lane 6), or without any antibody
(mock, lane 2). Immunoprecipitates were analyzed by PCR using primers specific for the aP2 promoter. As a control, a sample representing 1% of the total chromatin
was included in the PCR (input, lane 1).PPARγ target genes. Moreover, the presence of acetylated his-
tone H4 on the PPARγ binding site of the aP2 promoter sug-
gests that in the presence of cdk4 this promoter is active.
These results suggest that the positive effects of cdk4 on adi-
pogenesis are the result of cdk4-mediated increase of PPARγ
activity through cdk4 kinase activity.
Discussion
Cdk4 is the catalytic subunit of the cyclin D-cdk holoenzyme.
The kinase activity of this complex is induced in response to
extracellular signals, including growth factors, and translatesCELL METABOLISM : OCTOBER 2005signals from extracellular environment into cell cycle activation
(Matsushime et al., 1991). We have recently shown that the
transcription factor E2F1, which is the effector of the cyclin/
cdk pathway in cell cycle regulation, mediates the transition
between preadipocyte proliferation and adipocyte differentia-
tion through activation of the expression of PPARγ, which is
the master regulator of adipogenesis. The most studied role of
cdk4 is phosphorylation of the retinoblastoma family proteins
that repress E2F1 activity, thereby facilitating the release of
E2F1 from this complex, resulting in the activation of E2F1 tar-
get genes. Since cdk4 is an upstream regulator of the E2F1/
RB pathway, it is therefore likely that cdk4 also participates in245
A R T I C L Eadipocyte differentiation. Consistent with this, we found that cdk4
activity is required for adipogenesis. We propose that cdk4 plays
a dual role in this process (Figure 6). On the one hand, cdk4
participates in the clonal expansion phase of adipocyte differ-
entiation phosphorylating RB and therefore facilitating activa-
tion of E2F complexes, which will trigger the transcription of
PPARγ and likely other factors implicated in terminal differentia-
tion. This is so far consistent with the known functions of cdk4.
On the other hand, we found surprisingly that participation of
cdk4 was not limited to the control of cell cycle and E2F1 activ-
ity in the proliferative phase of adipocyte differentiation, but we
found that cdk4 has also a positive, cell cycle-independent role
in terminal differentiation and function of adipocytes. This is
supported by three main observations. First, cdk4 is expressed
in fully differentiated adipocytes in both human and mouse adi-
pose tissue (Figure 1; Phelps and Xiong, 1998). These dif-
ferentiated adipocytes do not express E2F1 (Fajas et al.,
2002b) and are not proliferating (Figure 1). Furthermore, cdk4
activity can be detected in differentiated 3T3-L1 adipocytes
and in mouse adipose tissue (Figure 1; Phelps and Xiong, 1998).
Second, inhibition of cdk4 activity with specific cdk4 inhibitors
impairs adipocyte differentiation regardless of whether the inhib-
itor is added before or after the proliferative phase of adipogen-
esis (Figure 2). Moreover, cdk4 inhibitors do not block the pro-
liferative phase of F442A preadipocyte differentiation process
and yet inhibit adipogenesis in this system. We cannot explain,
at present, why IDCX did not affect the clonal expansion phase
of F442A cells. Finally, cdk4 interacts with PPARγ, resulting in
increased transactivation activity of PPARγ (Figure 5). Further-
more, cdk4 can be found in the PPARγ-responsive element of
the aP2 promoter (Figure 5).
We can conclude from our results that cdk4 not only regu-
lates adipocyte differentiation, but also participates in adipo-
cyte biology. Cdk4 might act as a sensor of homeostatic sig-
nals. Nutrition and the subsequent hormonal signaling, such as
insulin, results in the activation of preadipocyte differentiation
and lipogenic pathways in already preexisting adipocytes. In
support of this hypothesis, the experiments in F442A cellsFigure 6. Schematic representation of cdk4 functions during adipogenesis
During the clonal-expansion phase, cdk4 activates E2F proteins, which were inhibited by RB. E2F activation will facilitate the expression of PPARγ, which in concerted
action with other transcription factors will trigger the expression of adipocyte-specific genes. During the terminal differentiation phase, cdk4 will directly activate PPARγ
through phosphorylation and inactivation of RB or other PPARγ corepressors. Alternatively, cdk4 could also activate through phosphorylation PPARγ coactivators.246show that inhibition of cdk4 in these cells results in decreased
lipogenesis rather than differentiation. As a proof of the partici-
pation of cdk4 in adipocyte biology, we observed decreased
insulin sensitivity, reduced glucose uptake, and decreased ex-
pression of genes implicated in lipogenesis and insulin signal-
ing such as IRS1 and 2, Glut-4, PI3K, FAS, or PEPCK in 3T3-
L1 adipocytes in which cdk4 activity was inhibited. In contrast
with this, we found that cdk4 inhibition resulted in increased
Glut-1 mRNA expression and enhanced basal glucose uptake
in 3T3-L1 adipocytes. We cannot explain at present how cdk4
regulates basal glucose uptake, and further studies are re-
quired.
The role of cdk4 as a growth signal sensor is underscored in
cdk4−/− mice, which have impaired postnatal pancreatic β cell
growth resulting in severe atrophy and diabetes (Mettus and
Rane, 2003; Rane et al., 1999). Furthermore, cdk4−/− and D-type
cyclin−/− mice show reduced body size, stressing the impor-
tance of cyclin D/cdk4 complex in the control of tissue growth
(Kozar et al., 2004; Mettus and Rane, 2003; Rane et al., 1999).
In contrast, cdk4R24C mice have increased body weight (Rane
et al., 1999). Cdk4R24C mice express a mutant cdk4 protein
(R24C) which is not inhibited by the cdk inhibitor p16, render-
ing cdk4 hyperactive (Zuo et al., 1996). Supporting our results
of the participation of cdk4 in adipose tissue development is
the observation that cdk4−/− mice have reduced adipose tissue
mass and adipocyte size, whereas cdk4R24C mice have in-
creased fat mass and adipocyte size (our unpublished data).
Unfortunately, a more in-depth metabolic analysis of these
mice is constrained by their diabetic status. We have, however,
demonstrated that primary embryonic fibroblasts from cdk4−/−
mice have lost their capacity to differentiate into adipocytes
(Figure 3). Most importantly, when we analyzed MEFs from mu-
tant cdk4R24C mice, which express hyperactive cdk4, we
found that these cells had increased adipogenic potential.
The positive role of cdk4 in adipogenesis is likely the result
of its interaction with PPARγ (Figure 5). Strikingly, the decreased
size of adipocytes observed in cdk4−/− mice (our unpublished
data) is reminiscent to what is observed in PPARγ+/− mice adi-CELL METABOLISM : OCTOBER 2005
Cdk4 and adipogenesispocytes (Barak et al., 1999; Kubota et al., 1999). It is also evoc-
ative of the decreased cdk4 activity observed upon energy re-
striction (Jiang et al., 2003), a situation where lipogenesis is
inhibited and PPARγ activity is also decreased. Interaction of
PPARγ with cdk4 is a new mechanism to activate PPARγ. This
broadens the range of signals that can activate the transcrip-
tional activity of PPARγ, further refining the response of the re-
ceptor, in conjunction with PPARγ ligands, to accommodate to
the cellular needs. Several members of the cdk family have
been shown to phosphorylate and modulate the activity of
other members of the nuclear-receptor superfamily, which also
act as mediators in a variety of signaling pathways through
integrating diverse phosphorylation events (reviewed in Roch-
ette-Egly [2003]). Of particular interest is the phosphorylation
and activation of the glucocorticoid receptor (Krstic et al.,
1997), the estrogen receptor α (Rogatsky et al., 1999), and
likely the progesterone receptor (Zhang et al., 1997) by cdk2.
Together with our results on regulation of PPARγ activity and
adipogenesis by cdk4, these studies clearly support a role for
cdks in hormonal signaling.
The effects of cdk4 on PPARγ activity could be the result of
a direct phosphorylation of PPARγ. When we tested this hy-
pothesis, we found that PPARγ was not phosphorylated in vitro
by cdk4 in several experimental conditions (data not shown),
suggesting that other mechanisms are mediating cdk4 activa-
tion of PPARγ. We know from our results that the kinase activity
of cdk4 is, however, required to activate PPARγ and promote
adipogenesis. One interesting hypothesis to explain the kinase
activity requirement could be the phosphorylation of PPARγ co-
factors by cdk4. In this scenario, PPARγ would recruit cdk4 to
the coactivator complex. Alternatively, the effect of cdk4 could
be the result of the phosphorylation and inactivation of the RB
protein, which has been shown to be a PPARγ repressor (Fajas
et al., 2002a) or the inactivation of other PPARγ corepressors
in differentiated adipocytes.
Since cdk4 is the catalytic subunit of type D cyclins, partici-
pation of cyclin Ds in adipogenesis is likely. Interestingly, cyclin
D3 KO mice are lean and smaller than wt mice (Sicinska et al.,
2003). Furthermore, expression of cyclin D3 is increased during
adipogenesis (Phelps and Xiong, 1998; Reichert and Eick,
1999). Adipose tissue phenotype in cyclin D3−/− mice is cur-
rently under study in our lab. On the other hand, cdk4 activity
can be modulated by the cdk inhibitors p21 and p27. In sup-
port of our results showing a positive role of cdk4 in adipogen-
esis, p21−/−, p27−/−, and p21/p27−/− mice had up to 4-fold in-
creases in body fat percentage compared to wild-type mice
(Naaz et al., 2004). This suggests that the release of cdk4 inhi-
bition, such as expected in p21−/− or p27−/− mice, might result
in increased cdk4 activity and therefore increased adiposity.
Adipose tissue growth, such as that observed during obesity,
is the result of both hypertrophy (increase in size) and hyperpla-
sia (increase in number) of adipocytes (Brook et al., 1972).
From our results, we can conclude that participation of cdk4 in
these processes is likely. Obesity and associated pathologies
are the second most common preventable cause of death. Dis-
covery of new targets may have a major impact on the associ-
ated metabolic syndromes. Identification of cdk4 as an adipo-
genic factor might result in new therapeutic strategies for the
treatment of obesity. Specific cdk4 inhibitors which have no
effects on cell cycle progression but retain its ability to inhibit
lipogenesis could be used for the treatment of obesity. ThisCELL METABOLISM : OCTOBER 2005would eliminate the undesired side effects of cdk4 inhibitors.
Furthermore, cdk4 should be therefore considered as a new
target for the search of genetic mutations predisposing to
obesity.
Experimental procedures
Materials
All chemicals, except if stated otherwise, were purchased from Sigma (St.
Louis, Missouri). Pioglitazone was a kind gift of Takeda Pharmaceuticals
(Osaka, Japan). Cdk4 inhibitor was purchased from Calbiochem (San
Diego, California). Antibodies were purchased from Santa Cruz Biotechnol-
ogy (Santa Cruz, California) except for the anti-BrdU antibody, which was
from Dako A/S (Glostrup, Denmark) and the anti-acetylated histone H4 (Lys
9) antibody, which was from Upstate Biotechnology (Lake Placid, New
York). Deoxy-D-[2-3H]glucose (2-DG; 26 Ci/mmol) was from Perkin Elmer
(Boston, Massachusetts). Purified porcine insulin was a gift from Eli Lilly
(Indianapolis, Indiana). The cdk4 kinase mutant (K35M) was a gift of Dr. M.
Serrano (CNIO, Madrid, Spain).
RNA isolation; quantitative real-time PCR
RNA isolation has been previously described (Hansen et al., 1999). Reverse
transcription of total RNA was performed at 37°C using the M-MLV reverse
transcriptase (Invitrogene SARL, France) and random hexanucleotides
primers, followed by a 5 min inactivation at 95°C. Quantitative PCR was
carried out by real-time PCR using a LightCycler and the DNA double-
strand-specific SYBR Green I dye for detection (Roche, Basel, Switzerland).
Results were then normalized to β actin levels. The primer pairs used in this
study are available upon request.
Cell culture
Cdk4−/−, cdk4R24C/R24C, and wild-type MEFs were obtained as previously
described (Humbert et al., 2000a, 2000b). MEFs, COS, Phoenix, and 3T3-
L1 cells were grown in DMEM, 10% fetal bovine serum (FBS). MEFs and
3T3-L1 cells were differentiated with DMEM, 10% serum, 0.5 mM 3-Isobu-
tyl-1methylxanthine (IBMX), 10 g/ml insulin, 1 M dexamethasone, and
100nM pioglitazone for 2 days. From the day 3 on, cells were incubated
with DMEM, 10% serum, 10 g/ml insulin, and 100 nM pioglitazone. Oil
Red O staining is described elsewhere (Ramirez-Zacarias et al., 1992). 3T3-
F442A preadipocytes were cultured in DMEM containing fetal calf serum
(10%), penicillin (200 units/ml), and streptomycin (50 mg/l) at 37°C in a
humidified atmosphere of 7% CO2. For adipocyte differentiation, the me-
dium was supplemented with insulin (50 nmol/l) once cells reached conflu-
ence. Medium was renewed every 2 days until the end of the experiment.
Human preadipocytes were obtained from subcutaneous abdominal adi-
pose tissue donors in agreement with French laws on biomedical research.
Separation and differentiation of preadipocytes was previously described
(Hauner et al., 1989). Glucose transport experiments were performed as
previously described (Carpene et al., 1993).
Retroviral construction and infection
Wild-type cdk4 and the kinase cdk4 mutant were cloned in a pBabe Puro
vector (cloning details are available upon request). Virus production and
infection of 3T3-L1 and MEF cells was performed as described previously
(Kim and Spiegelman, 1996). Infection efficiency was estimated at 90%.
Pooled clones were differentiated as described.
Immunofluorescence in 3T3-L1 cells
Cells were grown on coverslips. For BrdU incorporation, cells were incu-
bated 4 hr in the presence of BrdU, and an additional treatment of the
cells with 1.5N HCl for 10 min at 21°C was performed. After fixation and
permeabilization with 100% methanol, cells were incubated with antibodies
directed against cdk4 (Santa Cruz Biotechnology, California), PPARγ (Santa
Cruz Biotechnology, California), or BrdU (Dako A/S, Glostrup, Denmark).
Preparations were then incubated with a combination of Texas red-conju-
gated anti-rabbit IgG and FITC-conjugated anti-mouse IgG.
Mice
Twelve-week-old mice were used. C57BL/6J mice were maintained accord-
ing to European Union guidelines for use of laboratory animals. Mice had247
A R T I C L Ead libitum access to water and regular rodent chow (DO4, UAR, France).
For in vivo cell proliferation assays, 12-week-old mice were intraperitoneally
injected with BrdU (50 mg/kg body weight). After 18 hr, mice were sacrificed
and epidydimal white adipose tissue (WAT) was excised and fixed in 4%
formaldehyde.
Histological and immunofluorescence analysis in tissue sections
WAT was fixed as described and paraffin embedded. Sections were cut and
stained with hematoxylin and eosin or treated with 1.5 N HCl before incuba-
tion with BrdU (Dako A/S, Glostrup, Denmark)-specific antibody. Prepara-
tions were then incubated with a Texas red-conjugated anti-mouse IgG.
BrdU-positive cells were counted.
Transfections and plasmids
PcDNA3 vector was purchased from Stratagene (La Jolla, California). The
pcDNA3-cdk4 expression vector was a gift from Dr. C. Sardet. The PPARγ
promoter-reporter vector has been previously described (Fajas et al., 1997;
Fajas et al., 1998). All transfections were performed using the Lipofectamine
Plus reagent (GIBCO Life Technologies, Rockville, Maryland). Luciferase
and β-gal activity was measured as described (Fajas et al., 1997).
Protein expression assays
Whole-cell extracts were prepared as described (Fajas et al., 1997). SDS-
PAGE and electrotransfer was performed as described (Rocchi et al., 2001).
The membranes were blocked 1 hr in blocking buffer (PBS 0.5% Tween 20,
5% skim milk). Filters were first incubated overnight at 4°C with the indi-
cated primary antibodies and then for 1 hr at room temperature with a per-
oxidase conjugate secondary antibody. The complex was visualized with
ECL reagement.
Coimmunoprecipitation, pull-down, and chromatin
immunoprecipitation (ChIP) assays
For coimmunoprecipitation assays, whole-cell extracts were precleared
with protein A-agarose beads (Roche) during 30 min at room temperature,
an aliquot of the precleared lysates was saved as input. Extracts were then
centrifuged (5 min at 3000 rpm), and supernatants were immunoprecipi-
tated with the indicated specific antibodies during 2 hr at room temperature;
2–4 g of rabbit IgG (Sigma, St. Louis, Missouri) were used as negative
control (mock). Immunoprecipitates were then washed twice with IP buffer
(150 mM NaCl, 1% NP40 in 50 mM Tris/HCl buffer [pH 8]) and three times
with washing buffer (0.25 M KCl in PBS) and subjected to SDS-PAGE elec-
trophoresis. Chromatin immunoprecipitation assays were performed as de-
scribed previously (Takahashi et al., 2000). Briefly, proteins were formalde-
hyde crosslinked to DNA in confluent 3T3-L1 preadipocytes before
induction of differentiation or in cells induced with differentiation medium
for 7 days. Proteins were then immunoprecipitated using the indicated anti-
bodies; rabbit IgGs were used as mock; DNA was extracted from the immu-
noprecipitates, and PCR amplification was performed using promoter-spe-
cific oligonucleotide primers. For pull-down assays, in vitro translation of
PPARγ and cdk4 was performed with 35S-methionine (Perkin Elmer, Boston,
Massachusetts) in a TNT-coupled transcription-translation system following
manufacturer’s instructions (Promega, Madison, Wisconsin). GST fusion or
GST alone were expressed in Escherichia coli and purified on glutathione-
Sepharose beads (Amersham Biosciences, Uppsala, Sweden). For in vitro
interactions GST, GST-PPARγ-AB, GST-PPARγ-EDF, GST-cdk4, and GST-
cdk4 deletions (c-del positions 1–609, n-del positions 109–912) were incu-
bated with the labeled proteins in 200 l binding buffer containing 150 mM
NaCl, 1% Nonidet P-40, and 50 mM Tris (pH 8) at room temperature for 2
hr. Beads were washed three times with buffer containing 0.25 M KCl and
0.1% Tween 20 in PBS, followed by three washes with the same buffer
without Tween 20. The protein complexes were analyzed by autoradiogra-
phy after SDS-PAGE electrophoresis.
Kinase assays
Immunoprecipitated cdk4 from transfected COS cells, 3T3-L1 cells, or WAT
was used as kinase. cdk6/cycD3 kinase (Upstate, Charlottesville, Virginia)
was used as positive control. Immunoprecipitated cdk4 was washed once
with kinase buffer (25mM Tris/HCl [pH 7.5], 150 mM NaCl, 10 mM MgCl2,
1mM DTT) in the presence of a protease inhibitor cocktail (Sigma, St. Louis,
Missouri) and phosphatase inhibitors (5 mM Na P O , 50 mM NaF, 1 mM4 2 7
248vanadate). Kinase assay was performed during 30 min at 37°C in the pres-
ence of 40 M ATP and 8 Ci γ-33P ATP and the substrate reaction sub-
strate; recombinant PPARγ protein (Active Motif, Carlsbad, California) or Rb
protein (Santa Cruz, California). Reaction was stopped, boiling the samples
during 5 min in the presence of denaturing sample buffer. Samples were
then subjected to SDS-PAGE electrophoresis; gels were then dried in a gel
dryer for 1 hr at 80°C and exposed to an X-ray film.
Statistical analysis
Data are presented as means ±SEM. Group means were compared by fac-
torial analysis of variance (ANOVA). Upon significant interactions, differ-
ences between individual group means were analyzed by Fisher’s protected
least squares difference (PLSD) test. Differences were considered statistic-
ally significant at p < 0.05.
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